Johnson & Johnson Stock (US4781601046): Spravato Sales Projected Over $2.3 Billion This Year

Johnson & Johnson's Spravato, a ketamine-derived nasal spray for treatment-resistant depression, is expected to generate more than $2.3 billion in sales this year following FDA approvals for expanded indications.

Johnson & Johnson's Spravato nasal spray is projected to generate more than $2.3 billion this year, according to analysis highlighting its role in psychedelic medicine after FDA approval for treatment-resistant depression and major depressive disorder with acute suicidal ideation.

As of: May 05, 2026

By the AD HOC NEWS Editorial Team – Equity Coverage.

At a Glance

• Name: Johnson & Johnson
• ISIN: US4781601046
• Sector/Industry: Healthcare / Pharmaceuticals
• Headquarters/Country: New Brunswick, New Jersey, United States
• Primary Exchange: NYSE
• Trading Currency: USD

How Johnson & Johnson Makes Money: The Core Business Model

Johnson & Johnson operates through three main segments: Innovative Medicine, MedTech, and Consumer Health, with Innovative Medicine focusing on pharmaceuticals including immunology, oncology, and neuroscience products. The company generates revenue from global sales of prescription drugs, medical devices, and consumer products like over-the-counter medications.

In neuroscience, products like Spravato contribute to revenue by addressing unmet needs in mental health treatment. The business model relies on research and development investment, regulatory approvals, and partnerships to bring therapies to market.

Johnson & Johnson's Key Revenue and Product Drivers

Spravato, Johnson & Johnson's ketamine-derived nasal spray, is approved by the FDA for treatment-resistant depression and major depressive disorder with acute suicidal ideation and behavior. It is expected to generate more than $2.3 billion for Johnson & Johnson this year.

The product underwent rigorous seven pivotal trials leading to its FDA approvals. Johnson & Johnson is the only maker of Spravato, positioning it as a key driver in the psychedelic medicine space.

Industry Trends and Competitive Landscape

The mental health therapeutics market is expanding with demand for novel treatments like ketamine-based therapies for depression. Trends include increased focus on treatment-resistant conditions amid rising mental health awareness.

Competitors in neuroscience include companies developing similar antidepressants and psychedelic therapies, though Johnson & Johnson holds a unique position with FDA-approved Spravato.

Why Johnson & Johnson Matters to US Investors

Johnson & Johnson trades on the NYSE under ticker JNJ in USD, providing direct exposure for US investors to a leading pharmaceutical company with significant US revenue from products like Spravato. The company files with the SEC, ensuring transparency for American markets.

Its inclusion in major indices like the S&P 500 offers broad market relevance, with innovations in mental health treatments like FDA-approved therapies appealing to investors tracking healthcare growth.

Which Investor Profile Fits Johnson & Johnson – and Which Does Not?

Investors interested in established healthcare firms with diversified portfolios across pharmaceuticals and devices may find alignment with Johnson & Johnson's model. Those focused on mental health innovation note products like Spravato.

Profiles seeking high-growth tech or cyclical industries may look elsewhere, as Johnson & Johnson emphasizes stable healthcare fundamentals.

Risks and Open Questions for Johnson & Johnson

Risks include regulatory hurdles for new indications and competition in neuroscience. Patent expirations and pricing pressures in the US market pose challenges.

Open questions surround long-term adoption of Spravato and pipeline success in other areas.

Conclusion

Johnson & Johnson's Spravato stands out with projected sales over $2.3 billion this year following FDA approvals for key depression indications. The product positions the company in the emerging psychedelic medicine field. US investors benefit from its NYSE listing and SEC oversight.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.